TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02493894
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefazolin 1gram, every 6hours for 2 days
Study: NCT00976508
Drug: pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
Study: NCT01992159
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by subcutaneous injection
Study: NCT03939403
Drug: Time of administration of Corifollitropin Alfa
Normalized name: OIL OF CAMPHOR
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.
Study: NCT01698138
Drug: Onabotulinumtoxin A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %.
Study: NCT03103815
Drug: Amivita
Normalized name: Amjevita
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
Study: NCT02582359
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
Study: NCT02582359
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
Study: NCT00255476
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00255476
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01188174
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
Study: NCT03426982
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion dose of unfractionated heparin was adjusted by APTT
Study: NCT03426982
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion dose of unfractionated heparin was adjusted by anti-Xa
Study: NCT00464243
Drug: volinanserin
Normalized name: Volinanserin
DrugBank: Volinanserin (DB16351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02192541
Drug: Ziv-Aflibercept
Normalized name: Ziv-Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
Study: NCT02192541
Drug: Ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
Study: NCT02541383
Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
Study: NCT02541383
Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
Study: NCT02541383
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 16mg/kg every 8 weeks for 2 years
Study: NCT01633580
Drug: corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: long acting FSH
Study: NCT00128505
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02296047
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 µg inhalation once
Study: NCT02296047
Drug: salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 µg inhalation once
Study: NCT01578252
Drug: Ondansetron Tablets USP 8 mg
Normalized name: ondansetron Oral Tablet
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet once a day
Study: NCT01578252
Drug: Ondansetron Hydrochloride
Normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg tablet once a day
Study: NCT00177710
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05577273
Drug: Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
Study: NCT01967368
Drug: Intanza
DrugBank: Haemagglutinin-strain A(H3N2) (DB15475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
Study: NCT01967368
Drug: Vaxigrip
DrugBank: Haemagglutinin-strain A(H3N2) (DB15475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
Study: NCT01307605
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
Study: NCT02661711
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye.
Study: NCT00683904
Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Study: NCT00683904
Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Study: NCT02518503
Drug: Atorvastatin (≥20 mg)
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Atorvastatin (<20mg)
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT03800472
Drug: GLPG3312 MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
Study: NCT03800472
Drug: GLPG3312 FE MR
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
Study: NCT03800472
Drug: GLPG3312 MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
Study: NCT03800472
Drug: GLPG3312 MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
Study: NCT00812487
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive continuous insulin infusion through the vein.
Study: NCT02208297
Drug: Loteprednol Etabonate Gel (BID)
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
Study: NCT02208297
Drug: Vehicle Gel (BID)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
Study: NCT03359525
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous versus Intraarticular versus intravenous
Study: NCT00025441
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025441
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00025441
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025441
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00025441
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01162239
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
Study: NCT03932409
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy
Study: NCT03932409
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
Study: NCT03932409
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
Study: NCT02153580
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02153580
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02153580
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04665310
Drug: Envarsus XR
Normalized name: Envarsus XR
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus, extended-release tablets, a calcineurin inhibitor
Study: NCT02000622
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Study: NCT01995045
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrobulbar anesthesia
Study: NCT01995045
Drug: Bupivicaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrobulbar anesthesia
Study: NCT01809691
Drug: TAK-700
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, PO, twice daily
Study: NCT00466687
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg PO qd
Study: NCT01809691
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg, PO, q daily
Study: NCT04493554
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of vasopressin (20 IU) intranasally
Study: NCT02865642
Drug: Serotonin Uptake Inhibitors
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01819389
Drug: Imatinib and Nilotinib
Normalized name: Nilotinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04339361
Drug: lidocaine spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
Study: NCT00719797
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00719797
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00929864
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
Study: NCT03937635
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03937635
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00259129
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
Study: NCT01894815
Drug: Escitalopram oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
Study: NCT01977794
Drug: Bisoprolol/Amlodipine (Bisoprolol failed group)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Study: NCT02807805
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02807805
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02807805
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00929864
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Study: NCT00872625
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00872625
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00740051
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg once daily
Study: NCT00740051
Drug: Linagliptin Placebo
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0 mg placebo comparator for part 1 of study (to 18 weeks)
Study: NCT00740051
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-4mg for part 2 of study (weeks 19-52)
Study: NCT00991952
Drug: alvocidib
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00991952
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00048087
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
Study: NCT04522323
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INLYTA
Study: NCT04522323
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LENVIMA
Study: NCT00002543
Drug: gallium nitrate
Normalized name: Gallium Nitrate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03336333
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
Study: NCT03336333
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
Study: NCT03336333
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
Study: NCT03336333
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg tablets administered orally once daily.
Study: NCT01528046
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
Study: NCT02129777
Drug: Namilumab
Normalized name: Namilumab
DrugBank: Namilumab (DB13037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab subcutaneous injection
Study: NCT01537107
Drug: vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO